Innovative drugmaker Simcere Pharmaceutical Group Ltd. (2096.HK) said on Wednesday it expects to report a 2025 profit of between 1.3 billion yuan ($189 million) and 1.4 billion yuan, up 80.1% to 93.9% from a restated 722 million yuan for 2024.
The company said its revenue for the year ranged between 7.7 billion yuan and 7.8 billion yuan, up 16% to 17.6% year-on-year. Its adjusted profit for the year is expected to range between 1.25 billion yuan and 1.35 billion yuan, up 24.1% to 34.1%.
The company attributed the increases primarily to growth for its innovative pharmaceutical business, income from out-licensing agreements, and net gains in the fair value of its investment portfolio.
Simcere also disclosed that following its acquisition of Xianwei (Hainan) Biotechnology last October, comparative figures for 2024 were restated under merger accounting principles. After restatement, profit for 2024 was 722 million yuan, while adjusted profit was about 1 billion yuan.
Simcere’s shares opened higher on Thursday, but later reversed course to close at HK$12.35 by the midday break, down 5%. The stock is up about 4.6% so far this year.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
RELATED ARTICLES
-
Its accounting scandal wrapping up, Lufax faces bigger challenge from China’s economy
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- China’s biopharma sector enters the New Year on a high
-
Joinn’s ‘jumping’ monkey market hides core weakness
6127.HK603127.SHG
- BRIEF: China Resources Building Materials profit doubles in 2025
